TLR3 and neoplasm: PCSCs are responsible for tumor initiation, growth, and relapse in prostate cancer; consequently, TLR3 activation-based immunotherapy using polyinosinic:polycytidylic acid could be a good option for treatment, as it generates apoptosis and an inflammatory response in tumor cells (155).